Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Davis Polk Advises Valeant Pharmaceuticals International, Inc. on Its $1.5 Billion Refinancing
Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) in connection with a refinancing transaction…
Xencor, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $226.3 million public offering of common stock of…
Corvus Pharmaceuticals, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $69 million SEC-registered common stock offering by…
Davis Polk Advises Agilent Technologies on Its Acquisition of Advanced Analytical Technologies
Davis Polk is advising Agilent Technologies, Inc. on its acquisition of privately held Advanced Analytical Technologies, Inc…
Atara Biotherapeutics, Inc. Follow-On Offerings
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with two…
Anthem, Inc. $2.1 Billion Senior Notes Offering and Remarketing of Subordinated Notes
Davis Polk advised the representatives of the several underwriters in an SEC-registered offering of $2.1 billion in…
Aimmune Therapeutics Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $176 million SEC-registered offering of 5,500,000…
Davis Polk Advises ViewRay, Inc. on Its $59 Million Direct-Registered Equity Offering
Davis Polk advised ViewRay, Inc. in a direct-registered offering of 7,090,581 shares of ViewRay’s common stock and 1,418,116…
Celgene $4.5 Billion Notes Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on an SEC-registered…
Avadel Pharmaceuticals $143.7 Million Exchangeable Senior Notes Offering
Davis Polk advised the initial purchasers on a Rule 144A offering by Avadel Finance Cayman Limited, a wholly owned…